A collaboration to improve disease resistance in major crops through bioengineered proteins
Norwich, UK – 14 November 2022 – Leaf Expression Systems (Leaf), a contract research and development organisation that produces high value proteins and biomolecules using its innovative plant-based expression system today announced a collaboration with the John Innes Centre.
By using Leaf’s proprietary transient expression technology Supravec® in partnership with Professor Mark Banfield’s lab at the John Innes Centre, the team will explore the mechanistic biology of plant proteins involved in pathogen…
London BioScience Innovation Centre to be first occupier at Tribeca, London
The London BioScience Innovation Centre (“LBIC”) will open a new 37,127 sq. ft. state-of-the-art innovation centre at The Apex, one of five mixed-use buildings within the ‘Tribeca’ development in the heart of King’s Cross being delivered by Reef Group and Blackrock Alternatives, through its Real Estate business.
The Apex, scheduled for completion in autumn 2023, will build on LBIC’s existing provision to offer additional high-tech lab facilities to its growing customer base, with the new facility set to strengthen its…
Traditionally creating optimized, stable cell lines has been a time-consuming and complex process. Drawing upon proprietary technology - AMSBIO can deliver the high-quality cell lines you need with a single customer-defined knock-in in just 25% of the time required with conventional approaches.
Using a patented FAST-HDR plasmid vector system – AMSBIO can dramatically speed vector construction and reduce the time required to successfully isolate modified clones following transfection.
Using modular plasmid backbones, in which key components are readily swappable, AMSBIO can rapidly implement…
NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS
£16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling studies
Developing a pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore, which act through a novel mechanism of action, as treatments for Parkinson's and Amyotrophic Lateral Sclerosis (ALS)
Professor Seth Masters who identified a novel pathological…
Oxford, UK, 8 November 2022 –global techbio company PrecisionLife, pioneers in precision medicine for chronic diseases, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, an international biopharmaceutical group specialising in structure-based drug design targeting G protein-coupled receptors (GPCRs).
Sosei Heptares will leverage the extensive insights held in PrecisionLife’s DiseaseBank™- a repository of over 40 chronic disease studies - to determine the precision medicine opportunity of a drug targeting the nominated GPCR. The project aims to…
o2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition. Azadyne’s approach has shown striking efficacy in pre-clinical studies via the tRNA guanine transglycosylase (TGT) enzyme pathway against a range of autoimmune diseases without interfering with the body’s immune system.
As part of the kickstarter programme, o2h discovery will be providing small molecule synthetic chemistry to deliver improved medicines for patients with autoimmune disease, including Multiple Sclerosis.
Jason Rutt, CEO said: “We are very excited and appreciative of the o2h discovery…
FOR IMMEDIATE RELEASE: 1 November 2022
Nearly 70% of Life-Sci hiring is in the last quarter of the year
Biotech Search in 6-8 weeks means you can secure talent by end 2022
• From our sector experience the majority of recruitment is done in the last quarter
• Our specialist bespoke talent search solves the annual rush to make offers (and get acceptances) by December
• We do the heavy lifting in our Biotech Search package to get you where you need to be in 6-8 weeks
Singular Talent’s Biotech Search service is a bespoke service suited to meet the hiring needs of early-stage Biotechs to secure…
PhoreMost enters multi-target collaboration with targeted protein degradation leader Arvinas
PhoreMost to deploy its SITESEEKER® Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets
Cambridge, UK, 28 October 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-target collaboration with Arvinas, an industry leader in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding…
MD-T is proud sponsor of Fierce European TMF Summit. This is an excellent opportunity for organisations to share tools, strategies and methodologies to help over come dynamic TMF challenges.
Come meet the MD-T team at our booth and discuss the concerns your organisation may be facing to comply and implement the GDPR, UK Data Protection Act or any other international data protection regulation.
Mr. Damien Mair, chief development officer(CDO) at MDT, is also part of panel discussion below. Where he will highlight the updates and challenges with the compliance of GDPR and UK Data Protection…